Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
On Sept. 24, 2002, when I showed up at a meeting of the FDA Oncologic Drugs Advisory Committee, I had a pretty good idea that the drug on the agenda—AstraZeneca’s Iressa (gefitinib)—was having a surprising effect on some patients in third-line non-small cell lung cancer.
When I started fellowship training in the year 2000, the response from everyone when I mentioned my interest in lung cancer was nearly the same: “Are you sure?”
Lillian L. Siu discovered her passion while perusing employment ads in the Journal of Clinical Oncology.
Something felt wrong during one of Morhaf Al Achkar’s regular runs on the treadmill in late 2016. He started gasping for breath.
Soon after he was diagnosed with a dedifferentiated liposarcoma, C. Norman Coleman reached out to The Cancer Letter and the Cancer History Project to initiate a series of interviews about his life and career.
As a new deputy director at UPMC Hillman Cancer Center, Monica Baskin has assumed a level of responsibility that is unusual, if not unprecedented, for a population scientist at an NCI-designated cancer center.
In the late 1980s, R. J. Reynolds Tobacco Company made plans to market a new brand of menthol cigarette, Uptown.
What drew Jim Allison to T cells, Hagop Kantarjian to leukemia, or Betty Ford and Nancy Reagan to breast cancer advocacy?
